[go: up one dir, main page]

MX2019010370A - Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados. - Google Patents

Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados.

Info

Publication number
MX2019010370A
MX2019010370A MX2019010370A MX2019010370A MX2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A MX 2019010370 A MX2019010370 A MX 2019010370A
Authority
MX
Mexico
Prior art keywords
purified
compositions
cannabinoids
terpenes
compositions comprise
Prior art date
Application number
MX2019010370A
Other languages
English (en)
Inventor
Michael Cooper Jonathan
Levy Kurt
Reed Martin Jonathan
Geoffrey Reid Brian
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of MX2019010370A publication Critical patent/MX2019010370A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

En este documento se divulgan nuevas composiciones que comprenden un cannabinoide purificado y un terpeno purificado. En una realizacion, las composiciones comprenden uno o mas cannabinoides purificados. En una realizacion, las composiciones comprenden uno o mas cannabinoides purificados en combinacion con uno o mas terpenos purificados. En una realizacion, las composiciones comprenden proporciones no naturales. En una realizacion, las composiciones comprenden concentraciones no naturales. En una realizacion, las composiciones comprenden efectos inesperados y/o sinergicos.
MX2019010370A 2017-03-01 2018-03-01 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados. MX2019010370A (es)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US201762490465P 2017-04-26 2017-04-26
US201762490567P 2017-04-26 2017-04-26
US201762491160P 2017-04-27 2017-04-27
US201762491175P 2017-04-27 2017-04-27
US201762491980P 2017-04-28 2017-04-28
US201762491899P 2017-04-28 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
MX2019010370A true MX2019010370A (es) 2019-10-22

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010370A MX2019010370A (es) 2017-03-01 2018-03-01 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados.

Country Status (10)

Country Link
EP (1) EP3589129A4 (es)
CN (1) CN110582206A (es)
AU (1) AU2018227544A1 (es)
BR (1) BR112019018088A2 (es)
CA (1) CA3054690A1 (es)
CO (1) CO2019009413A2 (es)
IL (1) IL268929A (es)
MX (1) MX2019010370A (es)
PE (1) PE20200383A1 (es)
WO (1) WO2018160827A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
US10737198B2 (en) 2018-01-23 2020-08-11 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Dilute for the cannabinoid preparations
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
CN114980882A (zh) * 2019-11-26 2022-08-30 乐康瑞德有限公司 大麻素和番茄红素抗炎协同组合
CN115605289A (zh) * 2020-04-29 2023-01-13 利加尔有限合伙公司(Nz) 印迹聚合物及其使用方法
EP4188915A1 (en) * 2020-07-27 2023-06-07 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
US20240342197A1 (en) * 2021-01-29 2024-10-17 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
WO2023245185A1 (en) * 2022-06-17 2023-12-21 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) * 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
CA2931039C (en) * 2013-11-20 2022-07-12 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
MX2017010872A (es) * 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.

Also Published As

Publication number Publication date
CN110582206A (zh) 2019-12-17
CO2019009413A2 (es) 2019-09-09
EP3589129A1 (en) 2020-01-08
IL268929A (en) 2019-10-31
AU2018227544A1 (en) 2019-08-29
PE20200383A1 (es) 2020-02-24
CA3054690A1 (en) 2018-09-07
BR112019018088A2 (pt) 2020-03-24
WO2018160827A1 (en) 2018-09-07
EP3589129A4 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
MX2019010370A (es) Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados.
MX2017010872A (es) Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
AR129729A2 (es) Combinaciones fungicidas
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
UY38798A (es) Combinaciones, mezclas y composiciones fungicidas y usos de las mismas
ECSP19072372A (es) Moduladores de la expresión de pcsk9
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CO2020001325A2 (es) Combinaciones herbicidas sinérgicas
MX2019006769A (es) Composiciones que comprenden polisacaridos sulfatados.
AR112015A1 (es) Composiciones sólidas para administración oral
AR113419A1 (es) Formulación aerosolizable
CL2019001249A1 (es) Composiciones de recubrimiento y métodos de uso de las mismas.
UY37977A (es) Nuevas combinaciones de desfoliantes
UY38284A (es) Composiciones y métodos para agonizar el receptor cb2
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
MX385910B (es) Composiciones de fragancia que comprenden ciclohexanoato de etilo.
CL2021001246A1 (es) Moduladores de expresión irf5.
MX2023008764A (es) Composiciones y metodos para prevenir y tratar afecciones.
MX2020010424A (es) Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
NI201900006A (es) Combinaciã“n de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacã‰uticas de ã‰stos
JOP20190251A1 (ar) تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
AR110663A1 (es) Composición que comprende fluido de reemplazo de hemoconcentración
CL2020000586A1 (es) Moduladores de la expresión de enac.